Adair Newhall

Adair earned his MBA from the Darden Graduate School of Business Administration at the University of Virginia and his undergraduate degree from the University of Pennsylvania. 

​

Adair was a member of the Young Leaders Council of the Lance Armstrong Foundation and a co-founder of the UVa Venture Summit.

Adair is a Principal at Greenspring Associates (GA) and is responsible for sourcing and due diligence efforts on fund, direct, and secondary opportunities. Adair previously served as a Principal at Domain Associates, a leading healthcare-focused venture capital firm and GA fund manager. At Domain, he held board observer positions with several portfolio companies, including Applied Proteomics, Astute Medical, BioNano Genomics, CoLucid Pharmaceuticals, and Xagenic. He was previously involved as a board observer with Otonomy (NASDAQ: OTIC), which completed a successful initial public offering in August 2014. 

​

Prior to joining Domain in 2009, Adair worked in the Business Development group at Esprit Pharma where he assisted with multiple product acquisitions and the subsequent sale of the company to Allergan for $370M. Before that, he worked at ESP Pharma, which was acquired by PDL BioPharma (NASDAQ: PDLI) for $489M.

Adair is a member of Class 20 and served his fellowship at Greenspring Associates under the mentorship of Managing Partners Ashton Newhall and Jim Lim.